Clinical Trials
SMAC-AF Trial
Acronym: Atrial Substrate Modification with Aggressive Blood Pressure Lowering to Prevent AF
Purpose: Researchers analyzed whether aggressive blood pressure lowering reduces risk for recurrent atrial fibrillation after catheter ablation
Format: Randomized, open-label, parallel-assignment
Treatment Group: Aggressive treatment
Control Group: Standard treatment
Number of Participants: 184
Centers: 13
Summary: At 6 months, systolic blood pressure was lower in the aggressive-treatment group vs. the standard-treatment group (132.2 mm Hg vs. 135.4 mm Hg; P < .001), but there was no difference in the primary outcome of time to symptomatic atrial fibrillation, atrial tachycardia or atrial flutter lasting over 30 seconds more than 3 months after ablation (HR = 0.94; 95% CI, 0.65-1.38). Aggressive blood pressure treatment was more likely to benefit those older than 61 years (P for interaction = .013) and those with baseline systolic blood pressure < 140 mm Hg (P for interaction = .022).
Link to Cardiology Today Article: